In our retrospective review of 831 patients with myelodysplastic syndromes, 158 developed progression with a very poor outcome (median survival after evolution, 3.5 months). The survival of patients with adverse karyotypes ...

We have read with great interest the recent article by Qu et al . reporting the impacts of diff erent cytogenetic categories in the Revised International Prognostic Scoring System (IPSS-R) on the prognosis of primary ...

The International Prognostic Scoring System (IPSS) [1], the gold standard for risk assessment in Myelodysplastic syndromes (MDS), has been recently revised (IPSS-R). The authors proposed a new prognostic model including ...

Letter to the Editor

Treating patients with diffuse large Bcell lymphoma (DLBCL) remains a challenge, with a remission rate of 75% at 2 years from diagnosis. The International Prognostic Index (IPI) [1] and molecularcharacterization [2] are ...

Con el objetivo de mejorar la precisión diagnóstica y pronóstica en la enfermedad oncológica, se han valorado distintos factores pronósticos y modelos de predicción. Marco Maltoni, MD y cols diseñaron y validaron El ...

Myelodysplastic Syndromes (MDS) are a heterogeneous group of hematological diseases characterized by refractory cytopenia(s) and variable risk of leukemic progression. Cytogenetic analysis is important in day-to-day clinical ...

Peripheral T cell lymphoma (PTCL) is rare in the United States and Europe, accounting for about 10% of all lymphoma cases. In Latin America, PTCL accounts for about 15–20% of all lymphoma cases (Laurini et al, 2012). ...